At the recent ARCS Annual Conference, delegates in the Prescription and Non-Prescription Medicine Regulation stream were offered a detailed view into the transition from provisional to full approval. The session featured perspectives from two senior regulators: Dr Mohit Khera of the Therapeutic Goods Administration (TGA) and Chris James from Medsafe New Zealand.

Both speakers provided practical insights and real-world examples of how provisional approvals have evolved in recent years. While the regulatory frameworks in Australia and New Zealand differ in their details, they share a common goal of supporting early access to promising medicines while ensuring that the benefit continues to outweigh the risk as more data becomes available.

The Australian Perspective

Dr Khera began his presentation with a personal clinical story to emphasise that regulatory decisions ultimately affect patients. He traced the development of Australia’s provisional registration pathway, introduced in 2018 and significantly utilised during the COVID-19 pandemic for vaccines and treatments.

Provisional registration in Australia allows early access to medicines based on preliminary clinical data. It is initially granted for two years and can be extended twice, up to a total of six years. However, Dr Khera was clear that the intent is always full registration, which requires confirmatory data submitted through a Type S application.

He illustrated several case studies to highlight different scenarios. Some COVID-19 vaccines transitioned smoothly to full registration within two years. Others, such as the BA.1 strain vaccine, were withdrawn after the virus evolved and the initial benefit was no longer relevant.

Dr Khera reminded sponsors that clinical study plans must be robust and timelines realistic. If unexpected delays occur, such as those caused by slow recruitment or external factors like COVID-19, sponsors should engage with the TGA early. Adjustments can be made, provided the final submission occurs within the six-year window.

"Regardless of the role I have played as a clinician, academic or regulator, the patient has always remained at the centre," he said.

The New Zealand Experience

Chris James provided the New Zealand perspective, where provisional consent is granted under section 23 of the Medicines Act for up to two years. It may be renewed, depending on the application type. He outlined two defined pathways in use: one for medicines addressing unmet clinical need and another for managing stock shortages.

Provisional consent is particularly valuable in allowing conditions to be placed on the approval. These can relate to supply limits, prescribing restrictions or requirements for additional data. Mr James highlighted that stock shortages have become a more frequent driver of provisional applications, and Medsafe works closely with PHARMAC to ensure timely access where possible.

Conversion to full consent is encouraged once sufficient data becomes available. Medsafe generally expects a complete dossier for this transition, especially when the initial approval was based on limited information. If the data does not support a continued benefit-risk profile, renewal may not be granted.

"Provisional consent gives us a structured, time-limited approach to manage uncertainty while maintaining public confidence in medicine safety and quality," said Mr James.

Working Together and Moving Forward

During the discussion, audience questions explored the challenges of applying these frameworks to rare diseases, oncology trials, and changing clinical contexts. Both speakers acknowledged the need for flexibility and encouraged early communication with regulators to navigate these complex situations.

Work-sharing and collaborative review mechanisms, such as the Access Consortium, and Project Orbi were also discussed. Dr Khera confirmed that provisional approvals have been successfully granted through such frameworks, although final decisions remain the responsibility of each national regulator.

In closing, the speakers reminded the audience that provisional approval is not a shortcut. It is a carefully managed process designed to balance timely access with patient safety.

As Dr Khera summaris

ed, "If you take one thing away, let it be this: we transition from provisional to full registration to confirm that the early benefit we saw continues to hold true for the patients we serve."